血清尿酸作为痛风患者急性发作的替代终点:系统评价与荟萃回归分析
该系统评价与荟萃回归分析检索至2017年10月的多个数据库,纳入10项随机对照试验和3项开放标签扩展研究,评估血清尿酸(SU)与痛风急性发作的关系。基于随机对照试验的汇总数据未能确认SU与痛风发作的关联,但基于观察性生态学设计数据(包括较长疗程扩展研究)显示SU<6mg/dL与痛风发作减少相关。研究疗程和结局报告异质性限制了分析。
要点
- 基于随机对照试验汇总数据,SU与痛风发作的关联未能确认(P=0.47;R2=8%)。
- 基于观察性生态学设计数据(含较长疗程扩展研究),SU<6mg/dL与痛风发作减少相关。
- 降尿酸治疗疗程与发生痛风发作的患者比例呈负相关。
核心结论
- 基于随机对照试验汇总数据,SU与痛风发作的关联未能确认。
- 基于观察性生态学设计数据(包括较长疗程扩展研究),SU<6mg/dL与痛风发作减少相关。
研究设计与样本
- 系统评价与荟萃回归分析,检索多个数据库至2017年10月。
- 纳入比较任何降尿酸治疗与任何对照或安慰剂的随机对照试验,疗程≥3个月。
- 开放标签扩展研究数据纳入二次分析
- 共纳入10项随机对照试验和3项开放标签扩展研究。
- 数据由两名评价者独立提取标准化数据元素。
主要发现
- 随机对照试验(最长疗程24个月)的荟萃回归未显示痛风发作相对风险与SU<6mg/dL个体比例差异之间存在关联(P=0.47;R2=8%)。
- 事后分析计算了报告痛风发作比例的时间(月)与报告SU<6mg/dL个体比例的时间(月)之比,排除比值<2的研究后,剩余6项研究显示达到SU<6mg/dL的个体比例与痛风发作(按患者年)之间存在关联。
- 降尿酸治疗疗程与发生痛风发作的患者比例呈负相关。
- 观察性研究支持SU较低者痛风发作较少的趋势。
关键数值与推荐
- SU<6mg/dL为研究中使用的血清尿酸阈值。
- 随机对照试验荟萃回归:痛风发作相对风险与SU<6mg/dL个体比例差异的关联P=0.47;R2=8%。
- 事后分析排除报告时间比<2的研究后,剩余6项研究显示SU<6mg/dL个体比例与痛风发作(按患者年)之间存在关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究疗程和结局报告的变异性限制了分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The primary efficacy outcome in trials of urate lowering therapy (ULT) for gout is serum urate (SU). The aim of this study was to examine the strength of the relationship between SU and patient-important outcomes to determine whether SU is an adequate surrogate endpoint for clinical trials. METHODS: Multiple databases through October 2017 were searched. Randomized controlled trials comparing any ULT in people with gout with any control or placebo, ≥three months duration were included. Open label extension (OLE) trial data were included in secondary analyses. Standardized data elements were extracted independently by two reviewers. RESULTS: Ten RCTs and 3 OLE studies were identified. From the RCTs (maximum duration 24 months) meta-regression did not reveal an association between the relative risk of a gout flare and the difference in proportions of individuals with SU < 6mg/dL (P = 0.47; R2 = 8%). In a post hoc analysis, the ratio of the time in months at which the proportion of individuals having a flare was reported/time in months at which the proportion of individuals with SU < 6mg/dL was reported was calculated and studies where the ratio was <2 were excluded. Using the remaining 6 studies there was an association between proportion of individuals achieving SU < 6mg/dL and gout flares (over patient years). Duration of ULT was inversely associated with the proportion of patients experiencing a flare. Study duration and variability in reporting of outcomes limited the analysis. Observational studies supported the trend of fewer flares in those with lower SU. CONCLUSIONS: Based on aggregate clinical trial-level data an association between SU and gout flare could not be confirmed. However, based on observational ecological study design data-including longer duration extension studies-SU < 6mg/dL was associated with reduced gout flares.
引用
- Stamp L, Morillon MB, Taylor WJ, et al. Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis. Semin Arthritis Rheum. 2018. PMID: 29566967. doi:10.1016/j.semarthrit.2018.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。